J&J focus on biotech, innovation paying off

10/25/2004 | Newhouse News Service

Johnson & Johnson's decision more than five years ago to make a multibillion dollar investment in pharmaceutical research and development is beginning to pay dividends for the company that was foundering in the late 1990s with a failed line of drugs. Now J&J expects to submit six drugs to the FDA by the end of next year, thanks to a refocus of its business on biotechnology and innovation.

View Full Article in:

Newhouse News Service

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ